GU Ventures

OnDosis is a Swedish company founded in 2017, focusing on personalized medicine through its innovative dosing technology. The company specializes in delivering flexible and individualized dosing of oral medications, which are formulated as micro units like pellets, granules, mini tablets, or powders. By integrating digital technologies with traditional drug-based treatments, OnDosis aims to enhance disease management and improve patient adherence, particularly for conditions such as ADHD, pain management, and immunosuppression in organ transplant recipients. Their approach addresses the limitations of conventional tablets or capsules, providing greater convenience and improved health outcomes for patients. The technology developed by OnDosis is rooted in research from AstraZeneca and is supported by a network of strategic partners that assist in various core functions, including formulation, device development, and regulatory compliance.

Recycla is a recycling and waste management company that operates a marketplace platform designed to facilitate environmentally efficient recycling solutions. The platform connects users with quality-assured recycling companies, allowing individuals and organizations to easily find suitable partners for their recycling needs, whether at home, in businesses, or within tenant-owner associations. By providing a database of approved companies, Recycla enables users to efficiently match their specific recycling or waste management requests with the right service providers in their geographic area, promoting sustainable practices and cost-effective solutions in the recycling industry.

Cereno Scientific AB, established in 2012 and headquartered in Mölndal, Sweden, specializes in developing innovative therapeutics to prevent and treat cardiovascular and rare diseases. The company's primary focus is on epigenetic modulation, specifically through histone deacetylase inhibition (HDACi). Its lead product, CS1, is a phase II dual-acting antithrombotic drug candidate, designed to treat venous thrombosis and prevent stroke in patients with atrial fibrillation. Additionally, Cereno Scientific is exploring the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.